Source:http://linkedlifedata.com/resource/pubmed/id/18027210
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2007-11-20
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1054-3406
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1005-11; discussion 1029-32
|
| pubmed:meshHeading |
pubmed-meshheading:18027210-Clinical Trials as Topic,
pubmed-meshheading:18027210-Data Interpretation, Statistical,
pubmed-meshheading:18027210-Dose-Response Relationship, Drug,
pubmed-meshheading:18027210-Drug Industry,
pubmed-meshheading:18027210-Humans,
pubmed-meshheading:18027210-Research Design
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Discussion of the paper "Adaptive dose-ranging designs".
|
| pubmed:affiliation |
Biostatistics, AstraZeneca R&D, Mölndal, Sweden. carl-fredrik.burman@astrazeneca.com
|
| pubmed:publicationType |
Journal Article,
Comment
|